MannKind Exec's $269K Share Sale Is a Non-Event — Here's the Real Story Investors Should Focus On
MannKind's Stuart Tross sold 65,808 shares for tax purposes, but a 9% royalty tied to Tyvaso DPI — now threatened by United Therapeutics' Tresmi — is the real story.